Geneva, May 28 -- International Clinical Trials Registry received information related to the study (NCT06974110) titled 'Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors' on May 2.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: MOMA Therapeutics
Condition:
Advanced Solid Tumor
Metastatic Solid Tumor
Endometrial Cancer
MSI-H Cancer
Colorectal Cancer
Gastric Cancer
dMMR Cancer
Intervention:
Drug: MOMA-341
Drug: Irinotecan
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: June 2025
Target Sample Size: 132
To know more, visit...